Skip to main content

NXTC

Stock
Health Care
Biotechnology

Performance overview

NXTC Price
Price Chart

Forward-looking statistics

Beta
1.08
Risk
66.76%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.

Company info

SectorHealth Care
IndustryBiotechnology
Employees91
Market cap$38.9M

Fundamentals

Enterprise value-$37.1M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity10.46

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.77
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$679K
Put-call ratio

Macro factor sensitivity

Growth-0.7
Credit+6.2
Liquidity+0.1
Inflation-4.5
Commodities-2.0
Interest Rates-1.3

Valuation

Dividend yield0.00%
PEG Ratio-0.30
Price to sales
P/E Ratio-0.30
Enterprise Value to Revenue
Price to book0.22

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day
Ex. dividend day

News

Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing

NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Investment Research (December 25, 2023)
NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings

NextCure Inc (NASDAQ: NXTC) has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody. The Phase 1 dose-escalation portion of this Phase 1/2 open-label trial will evaluate the safety and tolerability of NC762 in patients with advanced or metastatic solid tumors and determine its maximum tolerated dose.

Benzinga (July 7, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free